Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; and TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults. It is involved in developing neurology products that include IONIS-HTTRx for Huntington's diseases; and IONIS-SOD1Rx and IONIS-C9Rx for amyotrophic lateral sclerosis and IONIS-MAPTRx for Alzheimer's diseases. The company is also developing severe and rare disease products, such as WAYLIVRA, a treatment for familial chylomicronemia syndrome; WAYLIVRA, a treatment for familial partial lipodystrophy; AKCEA-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; and IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity, IONIS-PKKRx/IONIS-PKK-LRx for hereditary angioedema, and IONIS-ENAC-2.5Rx for cystic fibrosis. In addition, its cardio metabolic and renal drugs include AKCEA-ANGPTL3-LRx for cardio metabolic disorders, IONIS-FXIRx for clotting disorders, AKCEA-APO(a)-LRx and AKCEA-APOCIII-LRx for cardiovascular diseases, and IONIS-DGAT2Rx for nonalcoholic steatohepatitis; IONIS-AGT-LRX for the treatment of resistant hyper tension; and IONIS-FXI-LRx for clotting disorders and IONIS-AZ4-2.5-LRx for cardiovascular diseases. Further, the company develops products for oncology that include IONIS-AR-2.5Rx and danvatirsen for cancers; and IONIS-HBVRx and IONIS-HBV-LRx for hepatitis b virus infection, and IONIS-FB-LRx for compliment meditated disease, and IONIS-JBI1-2.5Rx for gastrointestinal autoimmune diseases. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone760-931-9200
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$599.67 million
Profitability
Miscellaneous
Employees737
Next Earnings Date5/3/2019 (Estimated)
OptionableOptionable
Ionis Pharmaceuticals (NASDAQ:IONS) Frequently Asked Questions
What is Ionis Pharmaceuticals' stock symbol?
Ionis Pharmaceuticals trades on the NASDAQ under the ticker symbol "IONS."
How were Ionis Pharmaceuticals' earnings last quarter?
Ionis Pharmaceuticals Inc (NASDAQ:IONS) announced its quarterly earnings data on Wednesday, February, 27th. The company reported $2.42 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $2.46. The company had revenue of $192 million for the quarter, compared to analysts' expectations of $159.59 million. Ionis Pharmaceuticals had a net margin of 45.64% and a return on equity of 41.89%. Ionis Pharmaceuticals's revenue was up 14.3% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.03) EPS. View Ionis Pharmaceuticals' Earnings History.
When is Ionis Pharmaceuticals' next earnings date?
What guidance has Ionis Pharmaceuticals issued on next quarter's earnings?
Ionis Pharmaceuticals issued an update on its FY 2019 earnings guidance on Wednesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $725 million, compared to the consensus revenue estimate of $816.4 million.
What price target have analysts set for IONS?
8 Wall Street analysts have issued 1-year target prices for Ionis Pharmaceuticals' shares. Their predictions range from $48.00 to $82.00. On average, they expect Ionis Pharmaceuticals' stock price to reach $62.6250 in the next year. This suggests that the stock has a possible downside of 14.2%. View Analyst Price Targets for Ionis Pharmaceuticals.
What is the consensus analysts' recommendation for Ionis Pharmaceuticals?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ionis Pharmaceuticals in the last year. There are currently 1 sell rating, 6 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Ionis Pharmaceuticals.
What are Wall Street analysts saying about Ionis Pharmaceuticals stock?
Here are some recent quotes from research analysts about Ionis Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Ionis Pharmaceuticals, Inc. is a RNA-targeted drug discovery and development company which focuses on developing drugs for severe and rare diseases. Ionis Pharmaceuticals, Inc., formerly known as Isis Pharmaceuticals, Inc., is headquartered in Carlsbad, California. " (4/19/2019)
- 2. Cantor Fitzgerald analysts commented, ": $68 PT. Ionis is trading down -13% (vs. XBI -4%) after partner Roche’s (ROG-CH, NC) earnings call commentary this morning on the Huntington’s program. From Roche’s comments, we think definitive HD updates (cognition data, regulatory path) will not come until later this year or next, or potentially not until full Ph3 data (we estimate 2023+). We continue to think HD could be a high value indication longer term with high unmet need and get many investor questions on the program." (4/18/2019)
Has Ionis Pharmaceuticals been receiving favorable news coverage?
Media stories about IONS stock have trended neutral this week, according to InfoTrie Sentiment Analysis. The research firm identifies negative and positive news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ionis Pharmaceuticals earned a media sentiment score of 0.4 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 1.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
Who are some of Ionis Pharmaceuticals' key competitors?
Some companies that are related to Ionis Pharmaceuticals include Regeneron Pharmaceuticals (REGN), Takeda Pharmaceutical (TKPYY), Takeda Pharmaceutical (TAK), Alexion Pharmaceuticals (ALXN), ASTELLAS PHARMA/ADR (ALPMY), BioMarin Pharmaceutical (BMRN), Ono Pharmaceutical (OPHLF), Teva Pharmaceutical Industries (TEVA), Mylan (MYL), GRIFOLS S A/S (GRFS), Genmab A/S (GNMSF), Alnylam Pharmaceuticals (ALNY), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC) and SAGE Therapeutics (SAGE).
What other stocks do shareholders of Ionis Pharmaceuticals own?
Who are Ionis Pharmaceuticals' key executives?
Ionis Pharmaceuticals' management team includes the folowing people:
- Dr. Stanley T. Crooke, Founder, Chairman, CEO & Pres (Age 74)
- Dr. Brett P. Monia, Founder, COO, Sr. VP of Translational Medicine & Director (Age 58)
- Ms. Elizabeth L. Hougen, Sr. VP of Fin. & CFO (Age 57)
- Dr. Richard S. Geary, Sr. VP of Devel. (Age 61)
- Ms. B. Lynne Parshall, Sr. Strategic Advisor & Director (Age 65)
Who are Ionis Pharmaceuticals' major shareholders?
Ionis Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Scout Investments Inc. (0.22%), Peregrine Capital Management LLC (0.14%), BLB&B Advisors LLC (0.13%), State of Alaska Department of Revenue (0.01%), Virtu Financial LLC (0.01%) and Nisa Investment Advisors LLC (0.01%). Company insiders that own Ionis Pharmaceuticals stock include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Ionis Pharmaceuticals Inc, Joseph H Wender, Joseph Klein III, Patrick R O'neil, Richard S Geary, Sarah Boyce, Spencer R Berthelsen and Stanley T Crooke. View Institutional Ownership Trends for Ionis Pharmaceuticals.
Which major investors are selling Ionis Pharmaceuticals stock?
IONS stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC, Scout Investments Inc., BLB&B Advisors LLC, Clarus Wealth Advisors, Raymond James Trust N.A., State of Alaska Department of Revenue and First Hawaiian Bank. Company insiders that have sold Ionis Pharmaceuticals company stock in the last year include B Lynne Parshall, Brett P Monia, C Frank Bennett, Elizabeth L Hougen, Frederick T Muto, Joseph H Wender, Patrick R O'neil, Richard S Geary, Spencer R Berthelsen and Stanley T Crooke. View Insider Buying and Selling for Ionis Pharmaceuticals.
Which major investors are buying Ionis Pharmaceuticals stock?
IONS stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC, PFS Investments Inc., Highland Capital Management LLC, Gofen & Glossberg LLC IL, Berkshire Asset Management LLC PA, Wedbush Securities Inc., Strs Ohio and Meeder Asset Management Inc.. View Insider Buying and Selling for Ionis Pharmaceuticals.
How do I buy shares of Ionis Pharmaceuticals?
Shares of IONS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ionis Pharmaceuticals' stock price today?
One share of IONS stock can currently be purchased for approximately $72.99.
How big of a company is Ionis Pharmaceuticals?
Ionis Pharmaceuticals has a market capitalization of $10.10 billion and generates $599.67 million in revenue each year. The company earns $273.74 million in net income (profit) each year or $2.96 on an earnings per share basis. Ionis Pharmaceuticals employs 737 workers across the globe.
What is Ionis Pharmaceuticals' official website?
How can I contact Ionis Pharmaceuticals?
Ionis Pharmaceuticals' mailing address is 2855 GAZELLE COURT, CARLSBAD CA, 92010. The company can be reached via phone at 760-931-9200.
MarketBeat Community Rating for Ionis Pharmaceuticals (NASDAQ IONS)
MarketBeat's community ratings are surveys of what our community members think about Ionis Pharmaceuticals and other stocks. Vote "Outperform" if you believe IONS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IONS will underperform the S&P 500 over the long term. You may vote once every thirty days.
